Cell and Gene Therapies for HIV Cure: Developing a Pipeline (P01 Clinical Trial Not Allowed)
ID: 353440Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/353440

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-24-013.html
Timeline
  1. 1
    Forecast Posted Not available
  2. 2
    Forecast Due Not available
  3. 3
    Posted Apr 8, 2024 12:00 AM
  4. 4
    Due Jul 30, 2024 12:00 AM
Description

The National Institutes of Health (NIH) has posted a grant opportunity titled "Cell and Gene Therapies for HIV Cure: Developing a Pipeline (P01 Clinical Trial Not Allowed)". This grant aims to support multi-project research programs for the development, characterization, and advancement of gene- and cell-based approaches to achieve long-term remission or elimination of HIV. The funded projects will focus on basic science discovery and preclinical research activities, including test-of-concept studies in animal models. The ultimate goal is to evaluate these approaches in the clinic, making them scalable and deliverable. Applicants are required to include one or more private sector partners in their program. The grant does not have a cost-sharing or matching requirement. The eligible applicants include various institutions and organizations, such as Alaska Native and Native Hawaiian Serving Institutions, Faith-based or Community-based Organizations, and U.S. Territories or Possessions. Non-domestic (non-U.S.) entities are not eligible to apply, but non-domestic components of U.S. organizations are eligible. The grant opportunity will close on July 30, 2024, and more information can be found at the following link: http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-24-013.html. For any inquiries, please contact NIH Grants Information at grantsinfo@nih.gov.

Point(s) of Contact
grantsinfo@nih.gov
Files
Title
Posted
RFA-AI-24-013-Full-Announcement.html
4/16/2024
Similar Opportunities
Notice of Intent to Publish a Notice of Funding Opportunity for Cell and Gene Therapies for HIV Cure: Developing a Pipeline (P01 Clinical Trial Not Allowed)
Active
National Institutes of Health
The National Institutes of Health (NIH) plans to publish a Notice of Funding Opportunity (NOFO) for the development, characterization, and advancement of gene- and cell-based approaches to achieve long-term remission or elimination of HIV. This NOFO, expected to be published in April 2024, aims to solicit applications for cell and gene therapies for HIV cure. The NIH is seeking meaningful collaborations, interdisciplinary teams, and responsive applications. The NOFO will utilize the P01 (Research Program Projects) activity code. The estimated total program funding is $13,500,000, with an award ceiling of $2,200,000. It is anticipated that three awards will be granted. The application due date is expected to be in July 2024. The estimated award date and project start date are both set for March 2025.
Tailoring HIV Curative Strategies to the Participant (UM1 Clinical Trial Not Allowed)
Active
National Institutes of Health
The National Institutes of Health (NIH) has posted a grant opportunity titled "Tailoring HIV Curative Strategies to the Participant (UM1 Clinical Trial Not Allowed)". This opportunity falls under the category of Health and is a Cooperative Agreement type of funding instrument. The grant does not require cost sharing or matching. The purpose of this grant is to support the development of clinical research platforms that will enable future clinical trials to determine whether combinations of HIV cure strategies can be effective when optimally tailored to the participants. The goal is to inform the development and prioritization of more broad-based curative strategies that will be effective in all people living with HIV. This grant will support multidisciplinary teams to conduct coordinated basic and pre-clinical research. The teams will profile participants' intact, rebound-competent HIV reservoirs and immunologic backgrounds and use that information to develop and test combinations of HIV curative approaches that are specifically tailored to those participants. The grant has a closing date of July 30, 2024, and an award ceiling of $2,000,000. Eligible applicants include Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), Eligible Agencies of the Federal Government, Faith-based or Community-based Organizations, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Indian/Native American Tribal Governments (Other than Federally Recognized), Non-domestic (non-U.S.) Entities (Foreign Organizations), Regional Organizations, Tribally Controlled Colleges and Universities (TCCUs), U.S. Territory or Possession. Non-domestic (non-U.S.) Entities (Foreign Organizations) and non-U.S. components of U.S. Organizations are not eligible to apply. For more information and to apply for this grant opportunity, please visit the following link: [http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-24-011.html](http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-24-011.html). If you have any inquiries, you can contact NIH Grants Information at grantsinfo@nih.gov.
Opportunities for HIV Cure Strategies at the Time of ART Initiation (R01 Clinical Trial Not Allowed)
Active
National Institutes of Health
The National Institutes of Health is offering a grant opportunity titled "Opportunities for HIV Cure Strategies at the Time of ART Initiation (R01 Clinical Trial Not Allowed)". This grant aims to identify cure strategies suitable for administration at the start of combination antiretroviral therapy (cART) and/or at cART restart after an analytical treatment interruption (ATI), with the ultimate goal of achieving sustained treatment-free remission. The grant does not require cost sharing or matching requirements and falls under the category of Income Security and Social Services. The eligible applicants include various institutions and organizations such as Alaska Native and Native Hawaiian Serving Institutions, Faith-based or Community-based Organizations, and U.S. Territories or Possessions. The closing date for this grant opportunity is September 7, 2026. For more information and to apply, please visit the following link: [Opportunity Link](http://grants.nih.gov/grants/guide/pa-files/PAR-23-297.html). For any inquiries, you can contact NIH Grants Information at grantsinfo@nih.gov.
Opportunities for HIV Cure Strategies at the Time of ART Initiation (R21 Clinical Trial Not Allowed)
Active
National Institutes of Health
The National Institutes of Health is offering a grant opportunity titled "Opportunities for HIV Cure Strategies at the Time of ART Initiation (R21 Clinical Trial Not Allowed)". This grant aims to identify cure strategies suitable for administration at the start of combination antiretroviral therapy (cART) and/or at cART restart after an analytical treatment interruption (ATI), with the goal of achieving sustained treatment-free remission. The grant does not require cost sharing or matching. The funding instrument type is a grant, and the category of funding activity is Income Security and Social Services. The grant has a closing date of September 7, 2026, and an award ceiling of $275,000. Other eligible applicants include Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), Eligible Agencies of the Federal Government, Faith-based or Community-based Organizations, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Indian/Native American Tribal Governments (Other than Federally Recognized), Non-domestic (non-U.S.) Entities (Foreign Organizations), Regional Organizations, Tribally Controlled Colleges and Universities (TCCUs), and U.S. Territory or Possession. For more information and to apply, visit the following link: [Opportunity Link](http://grants.nih.gov/grants/guide/pa-files/PAR-23-296.html). For any inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
Mechanisms of Reciprocal Interactions between HIV Associated Neuroinflammation and CNS Persistence: Implications in HIV Neuropathogenesis and Cure (R01 Clinical Trial Not Allowed)
Active
National Institutes of Health
The National Institutes of Health (NIH) is offering a grant opportunity titled "Mechanisms of Reciprocal Interactions between HIV Associated Neuroinflammation and CNS Persistence: Implications in HIV Neuropathogenesis and Cure (R01 Clinical Trial Not Allowed)". This grant aims to examine the mechanisms of reciprocal interactions between HIV-associated neuroinflammation and CNS persistence in the setting of excellent virologic control. The research will utilize novel CNS cell systems, organoid models, and single cell technologies. The grant does not require cost sharing or matching. The funding instrument type is a grant, and the category of funding activity is health. The opportunity is posted on grants.gov and falls under the discretionary category. The CFDA number associated with this grant is 93.853. The eligible applicants include various institutions and organizations such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), eligible agencies of the Federal Government, faith-based or community-based organizations, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Indian/Native American Tribal Governments, non-domestic (non-U.S.) entities, regional organizations, Tribally Controlled Colleges and Universities (TCCUs), U.S. Territories or Possessions, and non-domestic (non-U.S.) components of U.S. Organizations. The closing date for this grant opportunity is November 8, 2024. For more information and to apply, visit the following link: [http://grants.nih.gov/grants/guide/rfa-files/RFA-MH-25-180.html](http://grants.nih.gov/grants/guide/rfa-files/RFA-MH-25-180.html). For any inquiries, contact NIH Grants Information at grantsinfo@nih.gov.